Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04692935

Enrollment

450

Registered

2021-01-05

Start date

2021-01-31

Completion date

2021-12-31

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of Lung

Keywords

Lung adenocarcinoma, Next-generation sequencing, Tumor genomic profiling, Ethnic differences

Brief summary

Lung adenocarcinomas (LUADs) from Asian ancestry are reported to have different genomic architectures compared with LUADs from Caucasian ancestry. However, due to lack of available cases, few studies controlled the clinical attributes during the comparisons of the genomic alterations. In this study, the investigators will identify Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital. Then, Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets \[MSK-IMPACT\]) will be identified in the GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations. Finally, genomic alterations regarding somatic mutations, copy number variations, fusions, mutational signatures, oncogenic pathways, and therapeutic actionability will be comprehensively compared between these two cohorts after adjusting age, sex, smoking status, and pathologic stage using propensity score matching. This study will elucidate important ancestry differences between Asian and Caucasian lung adenocarcinoma patients.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Primary lung adenocarcinoma * Broad-panel next-generation sequencing * Asian

Exclusion criteria

* Inadequate clinicopathological information * Low-quality next-generation sequencing

Design outcomes

Primary

Measure	Time frame	Description
Oncoprint of somatic mutations	July 2021	Association between genomic features and race
Copy number variations (CNVs)	July 2021	CNVs analysis by race
Mutational signatures	August 2021	Analysis of mutational signatures by race
Oncogenic pathways	September 2021	Analysis of oncogenic pathways by race
Therapeutic actionability	October 2021	Analysis of actionable alterations by race

Contacts

Primary ContactJian Zhou, MD

zhoujianmd@hotmail.com010-88326650

Outcome results